COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Livio Pagano, Francesco Passamonti, Alessandra Romano, Marco Salvini, Francesco Merli, Matteo G. Della Porta, Riccardo Bruna, Elisa Coviello, Ilaria Romano, Roberto Cairoli, Roberto Lemoli, Francesca Farina, Adriano Venditti, Alessandro Busca, Marco Ladetto, Massimo Massaia, Antonio Pinto, Luca Arcaini, Agostino Tafuri, Francesco MarchesiNicola Fracchiolla, Monica Bocchia, Daniele Armiento, Anna Candoni, Mauro Krampera, Mario Luppi, Valeria Cardinali, Sara Galimberti, Chiara Cattaneo, Elettra Ortu La Barbera, Roberto Mina, Francesco Lanza, Giuseppe Visani, Pellegrino Musto, Luigi Petrucci, Francesco Zaja, Paolo A. Grossi, Lorenza Bertù, Paolo Corradini, Enrico Derenzini, Monia Marchetti, Anna M. Scattolin, Alessandro Corso, Patrizia Tosi, Filippo Gherlinzoni, Carlo Gambacorti Passerini, Michele Cavo, Carmen Fava, Mauro Turrini, Carlo Visco, Patrizia Zappasodi, Michele Merli, Barbara Mora, Alessandro M. Vannucchi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04–11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11–1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.
Lingua originaleEnglish
pagine (da-a)371-377
Numero di pagine7
RivistaBritish Journal of Haematology
Volume195
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Covid-19
  • Antibody Formation
  • lymphoma
  • myeloma
  • SARS-CoV-2
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Viral
  • COVID-19
  • Female
  • Hematologic Neoplasms
  • Humans
  • Immunoglobulin G
  • Male
  • Middle Aged
  • Seroconversion
  • Young Adult
  • leukemia

Fingerprint

Entra nei temi di ricerca di 'COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies'. Insieme formano una fingerprint unica.

Cita questo